Study Details
Full Title
Protocol EA4231, A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements (HGBCL-DH-BCL2),(NCT 06649812)
Principal Investigator
Disha
Dalela
Protocol Number
PRO00119831
NCT ID
NCT06649812
Phase
II
Enrollment Status
Open to Enrollment